4. McKinney M, Arcasoy MO. Erythropoietin for oncology supportive care. Exp Cell Res. 2011;317(9):1246-1254.

5. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532-1542.


Continue Reading

6. Feinberg BA, Bruno AS, Haislip S, et al. Hemoglobin trends and anemia treatment resulting from concomitant chemotherapy in community oncology clinics. J Oncol Pract. 2012;8(1):18-23.

7. Reeves DJ, Quebe AK, Patel R. The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital. Pharmacy & Therapeutics. 2011;36(7):423-433.

8. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996-5010.

9. Boone JD, Walters CL, Fauci JM, Whitworth JM, Bevis KS, Alvarez RD. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in ovarian cancer patients. J Clin Oncol. 2012;30(15_suppl):Abstract 5060.

10. Dickinson KM, Sakr BJ. ESA use in women with cancer: Consequences of the 2008 FDA clinical alert. J Clin Oncol. 2012;30(15_suppl):Abstract 5040.

11. Karlsson T. Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents. ISRN Hematol. 2011;2011:108397.